110225 ⎘
Reverse transcribing DNA viruses; Details; Hepadnaviridae; Orthohepadnavirus, e.g. hepatitis B virus New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Synthesis, deprotection, analysis & purification of RNA & ribozymes
#302Compositions and methods for delivery of genetic material
#303Hiv-peptide-carrier-conjugates
#304Surface protein (HBsAg) variant of the hepatitis B virus
#305Melan-A- carrier conjugates
#306Surface protein (HBsAg) variant of the hepatitis B virus
#307Viral polymerase and modulation thereof
#308Circular expression construct for gene therapeutic applications
#309Vaccines containing ribavirin and methods of use thereof
#310HBV precore protein capable of forming particles
#311HBV drug resistance methods
#312Purification of HBV antigens for use in vaccines
#313Antigenic peptides
#314Nucleic acid coated particles suitable for temporary storage
#315Recombinant hepatitis B surface antigen
#316Hollow nanoparticle having modified cysteine residue and drug with the use thereof
#317Viruses and virus-like particles for multiple antigen and target display
#318Influenza immunogen and vaccine
#319Specificity exchangers that redirect antibodies to a pathogen
#320Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
#321Hollow nanoparticle of NBsAg large protein for drug delivery
#322Hla binding peptides and their uses
#323Angiotensin peptide-carrier conjugates and uses thereof
#324In vivo inhibition of hepatitis B virus
#325Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
#326Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof
#327Optimization of transgene expression in mammalian cells
#328Synthetic peptides that bind to the hepatitis B virus core and E antigens
#329Hapten-carrier conjugates and uses thereof
#330Viral variants and uses therefor
#331Vector for anti-HPV vaccine and transformed microorganism by the vector
#332Vaccines expressed in plants
#333Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
#334Nucleic acid vaccine compositions having a mammalian CD80/CD86 gene promoter driving antigen expression
#335Optimization of immunomodulatory properties of genetic vaccines
#336Methods and vectors for generating antibodies in avian species and uses therefor
#337Hepatitis C virus assay systems
#338Optimization of immunomodulatory properties of genetic vaccines
#339Viral variants with altered susceptibility to nucleoside analogs and uses thereof
#340Hepatitis B virus treatment
#341Host cells containing multiple integrating vectors
#342Method of protein production using mitochondrial translation system
#343Optimization of immunomodulatory properties of genetic vaccines
#344Inducing cellular immune responses to hepatitis B virus using peptide compositions
#345Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof
#346Induction of immune response against desired determinants
#347Nucleotide vector vaccine for immunization against hepatitis
#348Chimeric antigens for breaking host tolerance to foreign antigens
#349Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
#350Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
#351Chimeric antigens for eliciting an immune response